Public Company News & Press Release Distribution

Public Company News

APAC
Global

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...

2026-06-01 08:15 5234

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

TAIPEI, June 1, 2026 /PRNewswire/ -- MICROIP (TPEx: 7796), specializing in AI software and ASIC design services, will unveil its "AI Vehicle System Business Group" at COMPUTEX 2026 (Booth A1215a, TWTC Hall 1, June 2-5). Echoing the "AI Together" theme, the showcase focuses on edge AI, smart mobil...

2026-06-01 08:00 5143

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

TAIPEI, June 1, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today highlighted a strategic vision detailed by its found...

2026-06-01 08:00 4139

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...

2026-06-01 08:00 4451

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...

2026-06-01 08:00 4490

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-l...

2026-05-31 21:00 4031

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI * In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib,...

2026-05-31 08:09 5728

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

CHENGDU, China, May 31, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug con...

2026-05-31 08:00 8208

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating...

2026-05-30 22:01 9787

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-genera...

2026-05-30 21:51 9033

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift

HONG KONG, May 30, 2026 /PRNewswire/ -- As an emerging segment at the intersection of intelligent manufacturing and creative consumption, the global consumer 3D printing industry has become one of the fastest-growing markets in consumer technology. According to China Insights Industry Consultancy...

2026-05-30 11:58 15708

Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift

CLPS Incorporation Receives Nasdaq Notification Regarding Minimum Bid Price Requirements

HONG KONG, May 29, 2026 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS) today announced that it received a notification letter (the "Notification Letter") from Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated May 27, 2026, indicating th...

2026-05-30 08:16 5333

OCI Global Q1 2026 Trading Update

AMSTERDAM, May 30, 2026 /PRNewswire/ -- Hassan Badrawi, CEO of OCI Global: "During the first quarter, OCI made continued progress in executing its strategic priorities, including the completion of the sale of OCI Ammonia Holding to AGROFERT, the handover of Beaumont New Ammonia to Woodside, and t...

2026-05-30 00:35 7215

XCMG Secures Over $1 Billion in Orders at 8th International Customer Festival, Expanding Global Partnerships

XUZHOU, China, May 30, 2026 /PRNewswire/ -- XCMG concluded its 8th International Customer Festival, held from May 19 to 23 in Xuzhou, with more than 2,500 customers and business partners from around the world in attendance. During the event, signed orders exceeded US$1 billion, setting a new reco...

2026-05-30 00:30 11157

XCMG Secures Over $1 Billion in Orders at 8th International Customer Festival, Expanding Global Partnerships

AMTD's Successful Completion of Acquisition of Upper View Regalia Hotel in Malaysia for US$38 Million

PARIS and NEW YORK and LONDON, May 29, 2026 /PRNewswire/ -- AMTD Group Inc. ("AMTD Group"), AMTD IDEA Group (NYSE: AMTD; SGX: HKB), AMTD Digital Inc. (NYSE: HKD), and The Generation Essentials Group ("TGE", NYSE: TGE; LSE: TGE), a subsidiary of AMTD Digital Inc., (collectively, "AMTD") jointly an...

2026-05-29 23:07 7187

Lanvin Names Barbara Werschine as CEO

SHANGHAI, May 29, 2026 /PRNewswire/ -- Lanvin Group (NYSE: LANV), a global luxury fashion group, today announced that Maison Lanvin, the oldest couture house in Paris, has appointed Barbara Werschine as Chief Executive Officer. Ms. Werschine is an accomplished leader in the international luxury s...

2026-05-29 22:32 6814

Lanvin Names Barbara Werschine as CEO

2026-05-29 22:29 6467

XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies

BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received the second...

2026-05-29 22:10 7285

Cyient Named Leader Across All Three Quadrants of ISG Provider Lens™ 2026 Digital Engineering Services Report for North America

Company achieves clean sweep of all three quadrants — Augmented Design & R&D Services, Intelligent Operations & Connected Experiences, and Integrated Platform & Application Services — in the United States region HYDERABAD, India, May 29, 2026 /PRNewswire/ -- Cyient Limited, a global Intelligent ...

2026-05-29 22:00 5352

Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering

SHANGHAI, May 29, 2026 /PRNewswire/ -- Zhongchao Inc. ("Zhongchao" or the "Company") (NASDAQ: ZCMD), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the pricing of a best efforts public offering with gross proceeds ...

2026-05-29 22:00 8404

1 ... 47 48 495051 52 53 ... 1663